摘要
目的探讨厄贝沙坦联合阿托伐他汀钙对早期糖尿病肾病(DN)患者血糖、血脂、肾功能损伤及血清氧化低密度脂蛋白(ox-LDL)和高同型半胱氨酸(hcy)的影响。方法将160例在该院进行治疗的DN患者纳入研究,采用随机数字表法将患者分为A、B、C、D组,每组40例。A组采用常规治疗,B组采用厄贝沙坦治疗,C组采用阿托伐他汀钙治疗,D组采用联合治疗。比较4组患者血糖、血脂、肾功能和血清ox-LDL、hcy水平的差异。结果 4组患者治疗2个月后血糖、血脂和肾功能各项参数指标及血清ox-LDL和hcy水平均较治疗前有所改善,且D组患者血糖、血脂各项参数指标及尿素氮(BUN)、尿微量清蛋白/肌酐(UALB/Cr)、血清ox-LDL和hcy水平均明显低于其他三组,而肾小球滤过率估计值(eGFR)水平明显高于其他三组,差异均有统计学意义(P<0.05)。ox-LDL、hcy水平降低是厄贝沙坦联合阿托伐他汀钙治疗早期糖尿病患者临床疗效良好的影响因素。结论厄贝沙坦联合阿托伐他汀钙可有效改善早期DN患者血糖、血脂代谢和肾功能损伤,降低血清ox-LDL、hcy水平,值得临床推广应用。
Objective To investigate the clinical effect of irbesartan combined with atorvastatin calcium on the levels of serum glucose,lipid,renal function,oxidized low-density lipoprotein (ox-LDL)and hemocysteine (hcy) in the early treatment of diabetic nephropathy (DN).Methods A total of 160 DN patients with type Ⅱ diabetes in the hospital were enrolled and divided into group A,group B,group C and group D at random,40 cases in each group.The patients in the group A adopted traditional treatment,the group B with irbesartan,the group C with atorvastatin calcium,and the group D with irbesartan combined with atorvastatin calcium.The levels of serum glucose,lipid,renal function and ox-LDL,hcy levels were detected and compared among the four groups.Results After 2-month treatment,the levels of serum glucose,lipid,renal function,ox-LDL and hcy in the four groups were improved than those before treatment,and the levels of serum glucose,lipid BUN,UALB/Cr,ox-LDL and hcy in the group D were lower than those in the other three groups,while the value of eGFR was higher than that in the other three groups,the difference had statistically significant difference (P<0.05).The reduction of the levels of serum ox-LDL and hcy was independent factors of the clinical effect of irbesartan combined with atorvastatin calcium on early DN patients.Conclusion The application of irbesartan combined with atorvastatin calcium in early treatment of diabetic nephropathy could effectively improve the renal function and decrase the serum levels of ox-LDL and hcy,and the application is worthy of clinical promotion.
作者
陈海兰
CHEN Hailan(Kidney Department of Endocrinology,Chinese People's Liberation Army 266 Hospital,Chengde,Hebei 067000,China)
出处
《国际检验医学杂志》
CAS
2019年第10期1231-1235,共5页
International Journal of Laboratory Medicine
基金
承德市科学技术研究与发展计划项目(201606A090)